Advertisement


Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Opening Session Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Advertisement